Cinacalcet Cost-Effective When “Stopping Rules” Are Applied, Amgen Contends
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE draft appraisal concludes hyperparathyroidism therapy is unlikely to be considered cost-effective.